Fulcrum Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Apr 27, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(a) None.
(b) None.
(c)Director and Officer Trading Plans and Arrangements
On March 27, 2026, Alan Ezekowitz, a member of ourboard of directors, terminated a Rule 10b5-1 trading arrangement he had previously adopted on December 29, 2025 with respect to the sale of up to 124,713 shares of our common stock. The trading plan was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and was expected to remain in effect until December 31, 2026. As of the date of termination, Dr. Ezekowtiz had not sold any common shares under the terms of such trading plan. On March 27, 2026, Dr. Ezekowtiz adopted a trading plan for the potential exercise of vested stock options and the associated sale of up to 42,000 shares of our common stock. The trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is expected to remain in effect until April 1, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.